- Home
- BDTX vs PLX Comparison
BDTX vs PLX Comparison
Compare BDTX & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDTX | PLX |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 191.0M |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | BDTX | PLX |
|---|---|---|
| Price | $1.79 | $2.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $9.67 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.6M | 604.8K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.71 | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.77 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $1.41 |
| 52 Week High | $4.94 | $3.19 |
Technical Indicators
Market Signals| Indicator | BDTX | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.31 | 57.52 |
| Support Level | $1.76 | $2.06 |
| Resistance Level | $2.26 | $2.44 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 6.17 | 54.35 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.